Development and application of amphotericin B immunoassay for pharmacokinetic studies and therapeutic drug monitoring in critically ill patients

Article Biochemistry & Molecular Biology

Covalent Conjugation of Amphotericin B to Hyaluronic Acid: An Injectable Water-Soluble Conjugate with Reduced Toxicity and Anti-Leishmanial Potential

Ricardo Silva-Carvalho et al.

Summary: This study describes the safe and effective use of water-soluble HA-AmB imine conjugates for leishmaniasis treatment, which showed good anti-leishmanial activity without toxic effects.

BIOMACROMOLECULES (2022)

Add to Collection

Article Infectious Diseases

Comparative polymyxin B pharmacokinetics in patients receiving extracorporeal membrane oxygenation

Yury A. Surovoy et al.

Summary: This study aimed to describe the pharmacokinetics of polymyxin B in patients receiving veno-venous extracorporeal membrane oxygenation (ECMO) compared to critically ill patients without ECMO support. The results showed that the currently recommended dosage of polymyxin B is sufficient for ECMO patients and no dosage increase is required.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Review Infectious Diseases

Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections

Francelise B. Cavassin et al.

Summary: Polyenes, the oldest family of antifungal drugs introduced in the late 1950s, remain useful in the treatment of invasive fungal diseases due to their broad spectrum of activity, low resistance rate, and excellent clinical and pharmacological action despite their toxic potential. Focus has been placed on developing new products to minimize the known toxicity of the conventional drug.

INFECTIOUS DISEASES AND THERAPY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Sensitive LC-MS/MS Methods for Amphotericin B Analysis in Cerebrospinal Fluid, Plasma, Plasma Ultrafiltrate, and Urine: Application to Clinical Pharmacokinetics

Leandro Francisco Pippa et al.

Summary: This study developed LC-MS/MS methods for quantifying AmB in different matrices in neurocryptococcosis patients receiving treatment, successfully validating their applicability. Pharmacokinetic analysis revealed changes in drug clearance, volume of distribution, and unbound concentration of AmB at the initiation and conclusion of treatment in the assessed patient.

FRONTIERS IN CHEMISTRY (2021)

Add to Collection

Article Chemistry, Analytical

Development of ELISA formats for polymyxin B monitoring in serum of critically ill patients

Maksim A. Burkin et al.

Summary: Treating infections in critically ill patients often requires the use of last-line antibacterial drugs such as polymyxins. In critically ill patients, drug pharmacokinetics change significantly, affecting antibiotic concentrations and necessitating individual dosage adjustment to avoid therapeutic failures or toxic manifestations.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)

Add to Collection

Article Chemistry, Analytical